Ultragenyx Pharmaceutical (RARE) Change in Acquisitions & Divestments (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Change in Acquisitions & Divestments data on file, last reported at $88.0 million in Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments fell 35.77% year-over-year to $88.0 million in Q1 2026; TTM through Mar 2026 was $395.0 million, a 3424.9% increase from a year earlier, with the FY2025 full-year figure at $444.0 million, up 14700.0% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $88.0 million, up from $82.1 million in the prior quarter.
• Over the last five years, Change in Acquisitions & Divestments for RARE reached as high as $257.9 million in Q2 2022 and fell as low as -$287.7 million in Q4 2024.
• Historically, Change in Acquisitions & Divestments has averaged $39.4 million across 5 years, with a median of $82.1 million in 2025.
• Across the five-year window, Change in Acquisitions & Divestments jumped 386.02% in 2023 and plunged 8366.52% in 2024, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $1.3 million in 2022, then surged by 165.85% to $3.5 million in 2023, then plunged by 8366.52% to -$287.7 million in 2024, then surged by 128.54% to $82.1 million in 2025, then rose by 7.17% to $88.0 million in 2026.
• Per Business Quant data, the three most recent Change in Acquisitions & Divestments figures were $88.0 million in Q1 2026, $82.1 million in Q4 2025, and $135.6 million in Q3 2025.